With its leading technology and innovative ability, the company is a national project undertaker and a national technology center: it independently undertakes three "863" high-tech research projects of the Ministry of Science and Technology, such as CpG ODN hepatitis B vaccine, and is two national high-tech industrialization demonstration engineering bases of Haemophilus influenzae B conjugate vaccine and freeze-dried A C meningococcal polysaccharide conjugate vaccine of the National Development and Reform Commission. It is the "Kunming National Bio-industrial Base-Vaccine Production Pilot Center" of the National Development and Reform Commission and the "Bacterial Polysaccharide Combined Vaccine Technology Platform Center" of the Ministry of Science and Technology and the Ministry of Health. It is the "international scientific and technological cooperation base" of the Ministry of Science and Technology; It is Yunnan Vaccine Engineering Technology Research Center.
in research and development, the company always adheres to the research and development strategy of "filling the domestic vaccine gap and upgrading the vaccine industry", and takes innovation as the most important core competitiveness element of the company. R&D expenses have been invested more than 1 million yuan for many years, ensuring the smooth progress of technology research and development and the popularization and application of achievements. Since its establishment nine years ago, it has successfully developed a series of vaccine products with great market value through independent research and development. At present, the company has obtained the production approval number and marketed two products: "Haemophilus influenzae type B conjugate vaccine" and "freeze-dried meningococcal polysaccharide conjugate vaccine of groups A and C"; There are two products that have completed clinical research summary and trial production and are applying for production approval, such as "freeze-dried A C W135 Y group meningococcal polysaccharide vaccine"; There are two products that have completed the summary of clinical research and are under construction in GMP production workshop, such as "cell-free DTP combined vaccine"; There is one product under clinical research; Five vaccines have been accepted and registered in clinical research. In addition, there are more than a dozen vaccine products under research, most of which are "upgraded products" that replace the domestic market or "products that have been widely used abroad but have not been localized in China". In vaccine development and quality control technology, the company has obtained six invention patent certificates.
in September p>27, the company's first self-developed product "Haemophilus influenzae type B conjugate vaccine" was approved by SFDA, and it was successfully put into production and listed in Yuxi vaccine production base. The company realized the historic transformation from a research institution to a new vaccine enterprise with integrated research, production and marketing and a complete industrial chain. In September 29, the company's second product with independent intellectual property rights, "freeze-dried meningococcal polysaccharide conjugate vaccine", was approved for sale. In the next few years, the company will continuously introduce a series of vaccine products with excellent structure and great market prospects to the market.